



VENTURE VALUATION

Cambridge/Zurich: 14 March 2011

One Nucleus is delighted to announce a collaboration with Venture Valuation whereby One Nucleus members receive a free profile listing in the *Biotechgate* database. This will allow the One Nucleus member directory to be fully searchable via the One Nucleus website, as well as providing One Nucleus members with enhanced visibility to the global life science community.

Enabling member-to-member and member-to-non-member deal flow is a key driver for One Nucleus and the main reason so many companies join the largest life science membership organisation in Europe. A key facilitator of these benefits is the ability for visitors to our website to be able to identify suitable technology partners and customers in a timely manner. Tony Jones, Director of Business Development at One Nucleus commented 'the ability for visitors to identify One Nucleus member companies through routes other than One Nucleus is extremely beneficial'.

Biotechgate, administered by Venture Valuation, is one of the largest life science company databases globally, supporting EBD Group events such as BIOEurope and numerous leading life science cluster organisations such as BIOCOM, BIOTECCanada and Medicon Valley (MVA) in enabling their members and clients to search for suitable business partners. Patrik Frei, CEO of Venture Valuation stated, 'we are very happy to welcome One Nucleus, one of the key life sciences networks in Europe, as one of over 30 partners worldwide.'

About One Nucleus

Established in May 2010, One Nucleus is the result of the merger of ERBI and London Biotechnology Network. One Nucleus is a not-for-profit membership organisation for international life science and healthcare companies and the largest of its kind in Europe. The company is based in Cambridge UK and London, at the heart of Europe's largest cluster. The 450 members include pharmaceutical, biotech, medical device and diagnostic companies and associated technical and commercial Service Providers.

About Venture Valuation

Venture Valuation specialises in independent assessment and valuation of technology-driven companies in growth industries, mainly in Life Sciences (Biotech, Pharma, Medtech). In addition to valuation products, Venture Valuation offers high-quality, focused information services. Through their focus and unique position, they strive to fulfil and surpass customer needs and add value to the partnership.

About Biotechgate

In 2004, based on the requirement to have access to accurate and up-to-date industry intelligence, Venture Valuation implemented the Swiss Life Sciences Database. Information in this database, and subsequently created country portals, is encompassed in Biotechgate, the comprehensive, global Life Sciences database.

Using a bottom-up approach and partnering with local networks, associations and economic development agencies, Venture Valuation catalogues and categorises Life Sciences firms including Biotech, Pharma and Medtech companies, as well as associated suppliers, consultancies, investors, and non-profit organisations. Company profiles contain contact information, descriptions, details of products and/or services, and information regarding finance and management. Currently the database contains over 20,000 company profiles, 20,000 products and 25,000 management details.

ENDS

CONTACT:

One Nucleus

Tony Jones

Tel: +44 (0) 1223 896 450

tony@onenucleus.com

Venture Valuation/Biotechgate

Patrik Frei

Tel: +41 43 321 8660

p.frei@venturevaluation.com